Biosimilars

Brain Cancer

Breast Cancer

Business Management

CAR T-cell Therapy

COVID-19

Chronic Lymphocytic Leukemia

Colorectal Cancer

Disparities in Cancer Care

Gastrointestinal Cancer

Genitourinary Cancers

Global Oncology

Gynecologic Oncology

Head & Neck Cancers

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Mantle Cell Lymphoma

Melanoma & Skin Cancer

Multiple Myeloma

Myeloproliferative Neoplasms

Neoadjuvant HER2+

Non-Hodgkin Lymphoma

Oncology Nursing News

Ovarian Cancer

Pediatric Oncology

Precision Medicine in Oncology®

Prostate Cancer

Sarcomas/TGCT

Supportive Care

Urothelial Cancer

Dr Loretta J. Nastoupil details key efficacy data from the TRANSFORM trial investigating lisocabtagene as a second-line therapy for R/R LBCL, and Dr Marc S Hoffman comments on how to decide on an appropriate treatment in the second-line setting for high-risk R/R LBCL.

Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)

Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.

ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL

Drs Loretta J. Nastoupil and Marc S Hoffman explain the available treatment options for relapsed/refractory diffuse large B-cell lymphoma and what to consider when selecting a therapy in the second-line setting.

Currently Available Treatment Options for Patients With R/R DLBCL

Marc S. Hoffman, MD, provides an overview of recent updates in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

OncologyLive

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Subscribe

Print Subscription

eNewsletter

Articles

Radiation plus docetaxel improved disease-free survival and overall survival vs radiation alone in patients with head and neck squamous cell carcinoma 
unsuitable for cisplatin-based chemoradiation, regardless of patients’ prespecified prognostic groups, according to findings from a phase 2/3 trial.



Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC

Laura Dawson, MD, FRCPC, discusses data from the NRG/RTOG 1112 trial examining the addition of stereotactic body radiation therapy to sorafenib, the implications of the data for the locally advanced hepatocellular carcinoma treatment paradigm, and next steps for research.

NRG/RTOG 1112 Trial Highlights Benefit of Adding SBRT to Sorafenib in Locally Advanced HCC

Timothy Burns, MD, PhD, discusses the evolution of EGFR-targeted non–small cell lung cancer treatments, the importance of delineating small cell lung cancer subtypes, and the advantages of continued antibody-drug conjugate development across all areas of lung cancer.

Combinations Targeting EGFR and KRAS G12C May Advance NSCLC Treatment 

Amar U. Kishan, MD, discusses the safety results of MRI-guided SBRT compared with the current standard of care, highlights the benefits of using an MRI to guide radiation for patients with prostate cancer, and explains other areas where MRI-guided SBRT could explored.

MRI-Guided SBRT Could Represent Safer, More Precise Radiotherapy Option for Prostate Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

OncClub: Join the Chat on Trending Trials in Cancer

Specialty

1rem

primary

View

Videos

The Evolution of Immunotherapy in Cancer

Patient Selection for Checkpoint Inhibitor Therapy and Assessing Response

Emerging Checkpoint Inhibitors and Therapeutic Oncolytic Viruses

Adoptive T-Cell Approaches and Tumor Vaccine Strategies

The Future and the Era of Precision Immunology

Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

Emerging Agents in the Pipeline for Merkel Cell Carcinoma

Role of Immunotherapy in Merkel Cell Carcinoma

Howard Kaufman, MD

Patient Selection for Checkpoint Inhibitor Therapy and Assessing Response

Latest Conference Coverage